Cyclerion Therapeutics, Inc.
CYCN
$3.79
-$0.12-3.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | 40.66% | |||
| Gross Profit | -- | -244.27% | |||
| SG&A Expenses | -28.56% | 84.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -44.81% | 72.25% | |||
| Operating Income | 44.81% | -282.94% | |||
| Income Before Tax | 44.76% | -297.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.76% | -297.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.76% | -297.62% | |||
| EBIT | 44.81% | -282.94% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 45.36% | -260.28% | |||
| Normalized Basic EPS | 45.36% | -260.46% | |||
| EPS Diluted | 72.76% | -622.70% | |||
| Normalized Diluted EPS | 45.36% | -260.46% | |||
| Average Basic Shares Outstanding | 1.09% | 10.34% | |||
| Average Diluted Shares Outstanding | 1.09% | 10.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||